Extracellular Vesicle/Exosome Upstream Process Development: Maximizing Productivity to Accelerate… April 01, 2022 Biomanufacturing, EVs & Exosomes
Maintaining CQAs as Manufacturing Processes are Scaled from 2D to 3D Bioreactor Culture February 28, 2022 Biomanufacturing, Quality & Regulatory
MSCs “Versus” or MSCs “Via” T Cells for Cell & Gene Therapy? February 07, 2022 Biomanufacturing, Cell Therapy
Establishing a Working Range for Effective MSC-EV Dose December 16, 2021 Biomanufacturing, Cell Therapy, EVs & Exosomes
“One Does Not Simply Walk Into” a Therapeutic Cell Manufacturing Process… But the Long Road… November 03, 2021 BioEconomy, Biomanufacturing, Bioprocess Tools, Cell Therapy
It’s Not Rocket Science – “MSC-EVs” Have the Right Stuff July 14, 2021 Biomanufacturing, Cell Therapy, EVs & Exosomes, MSCs & Characterization
Environmental Analysis of Therapeutic hMSC Manufacturing: A Comparison of Multiple Bioprocess Systems June 08, 2021 Biomanufacturing, Quality & Regulatory
Identify & Define Your Cell Therapy’s Biomanufacturing Approach for Critical Process… April 27, 2021 Biomanufacturing, Quality & Regulatory
Critical Quality Attributes (CQAs): Know Their Importance & Limitations in Product & Process… April 27, 2021 Biomanufacturing, Quality & Regulatory
